2023-04-27 09:13:12 ET
- Rockwell Medical ( NASDAQ: RMTI ) said its international partner, Drogsan Pharmaceuticals, had submitted a marketing authorization application and GMP application for Triferic AVNU to the Turkish Medicines and Medical Devices Agency.
- Triferic AVNU is a ferric pyrophosphate citrate injection, used as a replacement therapy for iron, and indicated for the maintenance of hemoglobin levels in adult patients undergoing hemodialysis.
- Rockwell had signed license and supply agreements with Drogsan, a pharmaceutical company in Turkey, in June 2021, for the purpose of commercializing Triferic and Triferic AVNU in Turkey.
- As per the agreements, Rockwell has received an upfront payment and will be eligible for milestone payments and royalties on net sales. Drogsan will take charge of all regulatory approval and commercialization activities, while the Company will supply the product to Drogsan for Turkey.
For further details see:
Rockwell Medical Turkish partner Drogsan Pharma submits marketing application for Triferic AVNU